Full Press Release Details
to Participate in Cowen 41st Annual
LAUSANNE, Switzerland, February
25, 2021 - ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering
the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological
malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will participate in a fireside chat
at the Cowen 41st Annual Health Care Conference on Thursday, March 4, 2021, at 12:50 p.m. ET.
A live webcast of the fireside
chat will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com.
A replay of the webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics SA (NYSE:ADCT)
is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent
and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The Company develops
ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which
ADC Therapeutics has proprietary rights for its
targets. Strategic target selection
for PBD-based ADCs and substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical
and research pipeline of therapies for the treatment of hematological and solid tumor cancers. The Company has multiple PBD-based
ADCs in ongoing clinical trials, ranging from first in human to confirmatory Phase 3 clinical trials, in the USA and Europe, and
numerous preclinical ADCs in development.
Loncastuximab tesirine (Lonca,
formerly ADCT-402), the Company's lead product candidate, has been evaluated in a 145-patient pivotal Phase 2 clinical trial
for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% overall response rate (ORR),
which exceeded the target primary endpoint. On November 20, 2020, the U.S. Food and Drug Administration accepted the Biologics
License Application, granting priority review and setting a Prescription Drug User Fee Act (PDUFA) target action date of May 21,
2021. Camidanlumab tesirine (Cami, formerly ADCT-301), the Company's second lead product candidate, is being evaluated in
a 117-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma (HL) for which preliminary
data have demonstrated an 83% ORR, consistent with the Phase 1 clinical trial. The Company is also evaluating Cami in a Phase
1b clinical trial as a novel immuno-oncology approach for the treatment of various advanced solid tumors.
ADC Therapeutics is based in Lausanne
(Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please
visit https://adctherapeutics.com/ and follow the Company on Twitter